An investor in Celgene Corp. on Monday sued over Bristol-Myers Squibb Co.’s planned $74 billion acquisition of Celgene in Delaware Chancery Court, saying that the deal undervalued the company and its cancer therapies that are in the development pipeline.

The stockholder class-action lawsuit, filed by Hollywood, Florida-based law firm Mager Paruas, claimed that Bristol-Myers was “taking advantage” of a temporary decline in Celgene’s stock price to offer investors an estimated $102 in total value for each share they own in Celgene, which is based in New Jersey. Bristol-Myers’ headquarters are in New York City.